MwanzoGLTO • NASDAQ
add
Galecto Inc
Bei iliyotangulia
$ 0.57
Bei za mwaka
$ 0.46 - $ 3.70
Thamani ya kampuni katika soko
15.45M USD
Wastani wa hisa zilizouzwa
elfu 199.09
Uwiano wa bei na mapato
-
Mgao wa faida
-
Ubadilishanaji wa msingi
NASDAQ
Habari za soko
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (USD) | Mac 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | — | — |
Matumizi ya uendeshaji wa biashara | 5.74M | -57.45% |
Mapato halisi | -5.48M | 57.85% |
Kiwango cha faida halisi | — | — |
Mapato kwa kila hisa | -0.20 | 60.78% |
EBITDA | -5.74M | 57.43% |
Asilimia ya kodi ya mapato | — | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (USD) | Mac 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 27.17M | -48.97% |
Jumla ya mali | 32.48M | -49.75% |
Jumla ya dhima | 4.32M | -69.80% |
Jumla ya hisa | 28.16M | — |
hisa zilizosalia | 27.11M | — |
Uwiano wa bei na thamani | 0.55 | — |
Faida inayotokana na mali | -40.60% | — |
Faida inayotokana mtaji | -47.14% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (USD) | Mac 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | -5.48M | 57.85% |
Pesa kutokana na shughuli | -5.94M | 35.01% |
Pesa kutokana na uwekezaji | 5.65M | 311.21% |
Pesa kutokana na ufadhili | — | — |
Mabadiliko halisi ya pesa taslimu | elfu -374.00 | 95.15% |
Mtiririko huru wa pesa | -3.36M | 17.48% |
Kuhusu
Galecto Biotech is a biotechnology company that develops small molecules for the treatment of severe diseases, including fibrosis, cancer and inflammation. The company was founded in 2011 by leading galectin scientists and biotech executives from Sweden, United Kingdom, and Denmark. The company today is incorporated in the U.S., and has its operating headquarters in Copenhagen, Denmark.
The company builds on more than 10 years of research centering on the role of galectin-3 and LOXL-2, and the use of modulators of these proteins to treat fibrosis-related diseases and cancer. Combined with a strong patent estate, these assets give Galecto a unique therapeutic platform.
Galecto's lead product candidate, GB0139, is an inhaled inhibitor of galectin-3. GB0139 is being developed for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, in which there is high unmet medical need. Wikipedia
Afisa Mkuu Mtendaji (CEO)
Ilianzishwa
2011
Makao Makuu
Tovuti
Wafanyakazi
13
